Clinical Trials Logo

Graft vs Host Disease clinical trials

View clinical trials related to Graft vs Host Disease.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04728646 Withdrawn - Clinical trials for Graft Vs Host Disease

Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

Start date: September 2021
Phase: Phase 4
Study type: Interventional

To evaluate the safety and efficacy of Dextenza intracanalicular insert in patients with ocular graft-versus-host disease (GVHD).

NCT ID: NCT04280471 Withdrawn - Clinical trials for Acute Graft Versus Host Disease

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Start date: September 1, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of using an investigational procedure (fecal microbiota transplantation [FMT]) in treating patients with severe acute gut graft-versus-host-disease. The purpose of a fecal microbiota transplantation is to use feces from a healthy human donor to replace the abnormal gut bacteria in the recipient. One of the side effects of a stem cell transplant is the development of graft-versus-host disease (GvHD) in several organs including gut. GvHD is caused by the donated bone marrow or peripheral blood cells recognizing the recipient's body as foreign and attacking it. Acute gut GvHD is one of the leading causes of death after transplant. Recently, studies have shown that patients with reduced intestinal bacterial diversity in their stool during acute gut GvHD have higher overall mortality rates. The information learned from this study may offer FMT as a promising therapy for the treatment of severe acute gut graft-versus-host-disease.

NCT ID: NCT04204122 Withdrawn - Clinical trials for Ocular Graft-versus-host Disease

Vigamox Treatment for Ocular Graft-Versus-Host Disease

Start date: June 15, 2020
Phase: Phase 2
Study type: Interventional

In this study the investigators seek to prospectively measure the response of ocular graft-versus-host disease (GVHD) patients to treatment with topical Vigamox. The investigators will accomplish this by enrolling patients with bilateral ocular GVHD and treating one eye with topical Vigamox and the other eye with a placebo eye drop. By assessing the response to treatment with Vigamox, the investigators hope to identify a role for topical antibiotic treatment in ocular GVHD.

NCT ID: NCT04127721 Withdrawn - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Start date: September 22, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well itacitinib works in preventing graft versus host disease in patients with blood disorders undergoing donor stem cell transplantation. A donor transplantation uses blood-making cells from a family member or unrelated donor to remove and replace abnormal blood cells. Graft versus host disease is a reaction of the donor's immune cells against the patient's body. Itacitinib plus standard treatment may help prevent graft versus host disease in patients who have received a donor stem cell transplantation.

NCT ID: NCT04059757 Withdrawn - Clinical trials for Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)

Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

Start date: May 2022
Phase: Phase 2
Study type: Interventional

Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD) is a complication of allogeneic stem cell transplant which is usually treated with steroids. You are being asked to take part in this study because you have recently been diagnosed with GI-GVHD. The standard of care for GI-aGVHD is steroids. When aGVHD does not respond to steroids it is described as steroid-refractory aGVHD. There is no standard therapy for steroid-refractory GI-aGVHD. This study is a Phase II study. The main goal of a Phase II study is to see the efficacy and what side effects are seen with FMT as a treatment for GVHD. Fecal Microbiota Transplantation (FMT) is the transfer of fecal material from a healthy donor to a patient in order to restore the diversity of the intestinal microbiota. FMT is currently indicated for the treatment of recurrent Clostridium Difficile infection. FMT is considered experimental in this study, meaning it is not approved by the FDA for the treatment of GVHD.

NCT ID: NCT03986086 Withdrawn - Clinical trials for Hematologic Malignancy

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Start date: September 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is evaluate the safety and tolerability of MPH966, a neutrophil elastase inhibitor, and its ability to prevent graft-versus-host disease after hematopoietic stem cell transplant.

NCT ID: NCT03862079 Withdrawn - Clinical trials for Graft-versus-host Disease Prevention

Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well a fecal microbiota transplant with or without total gut decontamination works in preventing graft versus host disease in patients exposed to broad-spectrum antibiotics. Fecal microbiota transplantation is the administration by enema of fecal matter (stool) that includes helpful bacteria from a normal, healthy donor. Total gut decontamination uses antibiotics to remove/reduce the amount of bacteria in the digestive system. It is not yet known if a fecal microbiota transplant with or without total gut decontamination works better in preventing graft versus host disease compared to standard immunosuppressive therapies (therapies that lower the normal function of the immune system).

NCT ID: NCT03492502 Withdrawn - Clinical trials for Fecal Microbiota Transplantation in Graft vs. Host Disease

Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study aims to assess the safety and efficacy of autologous fecal microbiota transplantation (FMT) in gastrointestinal (GI) related graft-versus-host disease (GVHD). Stool for FMT will be prepared from pre-allogeneic stem cell transplantation (Allo-SCT) period. This strategy might offer a novel and safe therapeutic approach for these patients, who suffer from high disease related morbidity and mortality and are refractory to multiple treatments.

NCT ID: NCT02917148 Withdrawn - Acute GVH Disease Clinical Trials

MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease

Start date: September 2016
Phase: N/A
Study type: Observational

The goal of this research proposal is to identify a miRNA expression profile as a biomarker to diagnose and predict acute graft versus host disease (aGVHD) in patients who undergo allogeneic transplantation. This biomarker, once identified, will need validation in larger cohorts.

NCT ID: NCT02842372 Withdrawn - Clinical trials for Acute Graft Versus Host Disease in Skin

Ectoin Dermatitis Cream 7% as First-line Therapy of Acute Skin Graft Versus Host Disease

Start date: December 2015
Phase:
Study type: Observational

This is a non-interventional prospective study to investigate the treatment response to topical application with Ectoin Dermatitis Cream 7% as first-line therapy of grade I acute skin graft-versus-host disease.